tisagenlecleucel
AXP000013.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- CD19
- Originator
- University of Pennsylvania
- Sponsor
- Novartis
Names
| Name | Type | Source |
|---|---|---|
| tisagenlecleucel | preferred name, INN | curator, ncit |
| Kymriah | brand | ncit |
| CTL019 | code | ncit |
| CART-19 ambiguous | synonym | ncit |
| tisa-cel | synonym | ncit |
| Tisagenlecleucel-T | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- replication-incompetent lentiviral vector; murine anti-CD19 scFv, CD8 hinge and transmembrane region, 4-1BB (CD137) costimulatory domain, CD3 zeta signalling domain
- Transgenes
- anti-CD19 chimeric antigen receptor
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C102758
- Wikidata
- Q30314624
- FDA UNII
- Q6C9WHR03O
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| FDA | US | 2017-08-30 | approved | Kymriah | Patients up to 25 with refractory or second-or-later relapse B-cell precursor acute lymphoblastic leukaemia; adults with relapsed or refractory large B-cell lymphoma after two or more lines; adults with relapsed or refractory follicular lymphoma after two or more lines (accelerated approval). Not for primary CNS lymphoma | source |
| EMA | EU | 2018-08-23 | approved | Kymriah | Paediatric and young adult patients up to 25 years with B-cell acute lymphoblastic leukaemia that is refractory, in relapse after transplant or in second or later relapse; adults with relapsed or refractory diffuse large B-cell lymphoma or follicular lymphoma after two or more lines of systemic therapy | source |
| PMDA | JP | 2019-03-26 | approved | Kymriah | Relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia, and relapsed or refractory CD19-positive diffuse large B-cell lymphoma, each limited to patients meeting criteria on prior chemotherapy and on eligibility for or relapse after transplantation | source |
Clinical trials (55)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07676877 | Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma | Recruiting | Phase 1 | 2026-12-01 | 2027-12-31 | 18 | Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma |
| NCT04419909 | Retreatment With CTL019/CTL119 | Withdrawn | Phase 1 | 2026-05 | 2026-07-15 | 0 | Lymphoma, B-Cell |
| NCT07378969 | A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy | Recruiting | 2026-03-23 | 2039-08-31 | 30 | Secondary Malignancies of T-cell Origin | |
| NCT06785818 | Long-term Follow up Local Registry Study of Kymriah in South Korea | Recruiting | 2025-03-12 | 2039-12-30 | 500 | B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | |
| NCT06408194 | Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | Recruiting | Phase 1 | 2024-05-13 | 2027-02 | 28 | Acute Lymphoblastic Leukemia; Leukemia |
| NCT06003179 | Optimizing Lymphodepletion to Improve Outcomes in Patients Receiving Cell Therapy With Kymriah | Withdrawn | Phase 1 | 2024-04-05 | 2026-11 | 0 | Lymphoma, Large B-Cell, Diffuse |
| NCT05541341 | Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | Recruiting | 2023-11-24 | 2037-11-23 | 200 | Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma; Follicular Lymphoma | |
| NCT05888493 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma | Active not recruiting | Phase 3 | 2023-10-02 | 2028-07-25 | 109 | Follicular Lymphoma (FL) |
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Recruiting | Phase 2 | 2023-06-12 | 2030-06-30 | 396 | Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Follic Lymph to Diff Large B-Cell Lymphoma; Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence | Recruiting | Phase 1/2 | 2023-03-15 | 2027-03 | 26 | Acute Lymphoblastic Leukemia, in Relapse; B Acute Lymphoblastic Leukemia |
| NCT07039383 | A Real-world Study of the Effectiveness of Tisagenlecleucel in Acute Lymphoblastic Leukemia Patients | Completed | 2023-03-01 | 2024-06-18 | 79 | Acute Lymphoblastic Leukemia | |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) | Active not recruiting | Phase 2 | 2022-07-12 | 2027-07 | 30 | B-cell Acute Lymphoblastic Leukemia |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma | Withdrawn | Phase 1 | 2022-07 | 2025-01 | 0 | Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Non Hodgkin Lymphoma |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) | Withdrawn | Phase 2 | 2022-01-31 | 2022-10-31 | 0 | Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT05199961 | Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel | Terminated | 2022-01-25 | 2022-09-13 | 4 | Lymphoma, Large B-Cell, Diffuse | |
| NCT04890236 | Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study | Completed | Early phase 1 | 2022-01-13 | 2024-03-20 | 4 | Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma |
| NCT04156659 | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL | Withdrawn | Phase 2 | 2021-11-30 | 2022-11-30 | 0 | B-cell Acute Lymphoblastic Leukemia |
| NCT05075603 | Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy | Completed | Phase 1 | 2021-07-29 | 2024-12-18 | 17 | DLBCL Arising From Follicular Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma |
| NCT04855253 | Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL | Suspended | Phase 1/2 | 2021-06-09 | 2027-09 | 30 | DLBCL; DLBCL Arising From Follicular Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma |
| NCT04161118 | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma | Terminated | Phase 2 | 2021-05-12 | 2023-02-24 | 3 | Non Hodgkin Lymphoma |
| NCT07103486 | A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Completed | 2021-04-01 | 2023-01-31 | 264 | Diffuse Large B-Cell Lymphoma | |
| NCT05349201 | CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) | Completed | 2020-12-09 | 2021-05-28 | 273 | Acute Lymphoblastic Leukemia (ALL); Diffuse Large B-Cell Lymphoma (DLBCL) | |
| NCT04225676 | Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) | Terminated | Phase 2 | 2020-10-19 | 2021-10-19 | 5 | Acute Lymphoblastic Leukemia |
| NCT03628053 | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia | Withdrawn | Phase 3 | 2020-06-05 | 2025-10-08 | 0 | Acute Lymphoblastic Leukemia |
| NCT04234061 | Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma | Active not recruiting | Phase 2 | 2020-04-07 | 2027-09-01 | 20 | Mantle Cell Lymphoma Recurrent |
| NCT04276870 | Orphan Indications for CD19 Redirected Autologous T Cells | Recruiting | Phase 2 | 2020-03-12 | 2028-03-10 | 133 | Infants With Very High Risk KMT2A B-ALL; Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation; Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL |
| NCT05541328 | Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel | Completed | 2020-02-03 | 2021-02-05 | 169 | Diffuse Large B-cell Lymphoma | |
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | Recruiting | Phase 3 | 2019-11-21 | 2027-03-31 | 200 | B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma |
| NCT03876769 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | Active not recruiting | Phase 2 | 2019-06-24 | 2027-10-19 | 121 | B-Cell Acute Lymphoblastic Leukemia |
| NCT03876028 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients | Terminated | Phase 1 | 2019-06-11 | 2021-11-01 | 10 | Diffuse Large B-cell Lymphoma |
| NCT03570892 | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma | Completed | Phase 3 | 2019-05-09 | 2021-05-06 | 330 | Non-Hodgkin Lymphoma |
| NCT03610724 | Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients | Completed | Phase 2 | 2019-02-15 | 2021-07-27 | 34 | Non-Hodgkin Lymphoma |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | Completed | Phase 1 | 2019-01-01 | 2022-04-14 | 13 | Primary CNS Lymphoma; Refractory Primary CNS Lymphoma; Relapsed Primary CNS Lymphoma |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Active not recruiting | Phase 2 | 2018-12-18 | 2024-02-09 | 150 | Acute Lymphoblastic Leukemia; Large B-cell Lymphoma |
| NCT03568461 | Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma | Completed | Phase 2 | 2018-11-12 | 2020-11-24 | 98 | Follicular Lymphoma |
| NCT03630159 | Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients | Completed | Phase 1 | 2018-10-09 | 2021-07-20 | 12 | Diffuse Large B-cell Lymphoma |
| NCT03123939 | Phase III B in Acute Lymphoblastic Leukemia | Completed | Phase 3 | 2017-04-24 | 2020-10-13 | 69 | Acute Lymphoblastic Leukemia |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | Terminated | Phase 2 | 2016-10 | 2018-12-12 | 1 | Leukemia, Acute Lymphoblastic |
| NCT02906371 | Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | Completed | Phase 1 | 2016-08 | 2020-03-11 | 80 | Lymphoblastic Leukemia, Acute, Childhood |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | Terminated | Phase 2 | 2016-06 | 2019-02 | 6 | Multiple Myeloma |
| NCT02167360 | Study of Efficacy and Safety of CTL019 in Adult ALL Patients | Withdrawn | Phase 2 | 2016-06 | 2017-01-11 | 0 | B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | Terminated | Early phase 1 | 2016-01-29 | 2018-10-15 | 20 | LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) |
| NCT02529813 | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | Phase 1 | 2015-12-16 | 2021-11-08 | 26 | Acute Biphenotypic Leukemia; Acute Lymphoblastic Leukemia; Blasts 5 Percent or More of Bone Marrow Nucleated Cells; CD19 Positive; Minimal Residual Disease; Non-Hodgkin Lymphoma; Small Lymphocytic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia |
| NCT02624258 | Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma | Terminated | Early phase 1 | 2015-11 | 2019-06-05 | 2 | Hodgkin Lymphoma |
| NCT02445248 | Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients | Completed | Phase 2 | 2015-07-29 | 2022-12-22 | 115 | Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients | Completed | Phase 2 | 2015-04-08 | 2020-01-21 | 80 | B-cell Acute Lymphoblastic Leukemia |
| NCT02228096 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients | Completed | Phase 2 | 2014-08-14 | 2018-05-29 | 75 | B-cell Acute Lymphoblastic Leukemia; Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia |
| NCT02135406 | CART-19 for Multiple Myeloma | Completed | Phase 1 | 2014-05 | 2015-09 | 13 | Multiple Myeloma |
| NCT02030847 | Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia | Completed | Phase 2 | 2014-02-27 | 2018-04-26 | 42 | Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options |
| NCT02030834 | Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas | Completed | Phase 2 | 2014-02-05 | 2019-09-16 | 63 | Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas |
| NCT01747486 | Dose Optimization Trial of CD19 Redirected Autologous T Cells | Completed | Phase 2 | 2013-01-02 | 2017-12-13 | 42 | Adult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLL |
| NCT01626495 | Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma | Completed | Phase 1/2 | 2011-08-17 | 2018-05-07 | 73 | B Cell Leukemia; B Cell Lymphoma |
| NCT01551043 | Allo CART-19 Protocol | Terminated | Phase 1 | 2010-09 | 2015-05 | 2 | Acute Lymphocytic Leukemia |
| NCT01029366 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | Completed | Phase 1 | 2010-03-17 | 2015-07 | 26 | Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Hematopoietic/Lymphoid Cancer; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma |
| NCT03601442 | Managed Access Programs for CTL019, Tisagenlecleucel | Available | Leukemia; Lymphoma; Off-label Indications |
Unconfirmed matches (32)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT07932262 | An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 | Not yet recruiting | Phase 1/2 | 2027-01 | 2028-06 | 36 | ANCA Associated Vasculitis (AAV); IIM; Immune Thrombocytopenic Purpura; Multiple Sclerosis; Pemphigus Vulgaris (PV); Rheumatoid Arthritis (RA); Systemic Sclerosis (SSc) | name in title: CART-19 |
| NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Not yet recruiting | Phase 1/2 | 2026-12 | 2029-06 | 30 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | name in intervention: CART-19 |
| NCT07371403 | MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia | Recruiting | 2026-02-20 | 2029-01 | 12 | Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia Not Having Achieved Remission; Acute Lymphoblastic Leukemia Recurrent; Acute Lymphoblastic Leukemia Refractory; Acute Lymphoblastic Leukemia With Failed Remission | name in intervention: CART-19 | |
| NCT06839976 | CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus | Recruiting | Phase 1/2 | 2025-05-06 | 2030-02-28 | 24 | CAR T Cell; CART19; Cell Therapy; Lupus; Lupus Nephritis (LN); SLE; Systemic Lupus Erythematosus (SLE) | intervention named: CART-19 |
| NCT06189157 | MB-CART19.1 in Refractory SLE | Recruiting | Phase 1/2 | 2024-08-12 | 2027-09-30 | 29 | SLE - Systemic Lupus Erythematosus | name in intervention: CART-19 |
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies | Recruiting | 2024-05-05 | 2040-12-31 | 40 | Acute Lymphatic Leukemia; B-cell Non Hodgkin Lymphoma; Childhood Non-Hodgkin Lymphoma; Chronic Lymphatic Leukemia; Melanoma Stage III; Melanoma Stage IV; Pediatric ALL | name in intervention: CART-19 | |
| NCT06101381 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma | Recruiting | Phase 1/2 | 2024-03-21 | 2028-12 | 81 | Leukemia, Acute Lymphoblastic; Lymphoma, Non-Hodgkin | intervention named: CART-19 |
| NCT06179524 | CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | Recruiting | Phase 2 | 2024-01-03 | 2025-06-30 | 100 | Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia | name in intervention: CART-19 |
| NCT06160362 | The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL) | Unknown | 2023-10-31 | 2025-12 | 20 | Non-hodgkin Lymphoma,B Cell | name in intervention: CART-19 | |
| NCT06271369 | Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study. | Completed | 2022-08-11 | 2023-02-15 | 613 | Diffuse Large B-cell Lymphoma | name in title: tisa-cel | |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma | Recruiting | Phase 1 | 2021-06-02 | 2025-06-01 | 10 | Non-Hodgkin's Lymphoma Refractory; Non-Hodgkin's Lymphoma, Relapsed; Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia | name in title: CART-19 |
| NCT04778579 | Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy | Unknown | Phase 2 | 2021-05-11 | 2024-12-31 | 50 | Acute Lymphoid Leukemia | intervention named: CART-19 |
| NCT05270772 | CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL | Unknown | Phase 1 | 2021-02-25 | 2022-07-15 | 9 | CD19+ Relapse/Refractory B-ALL | name in intervention: CART-19 |
| NCT04173988 | Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Unknown | Early phase 1 | 2020-01-09 | 2024-10-20 | 6 | ALL, Childhood B-Cell | name in intervention: CART-19 |
| NCT04204161 | A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma | Unknown | Phase 1 | 2019-10-08 | 2021-10-30 | 30 | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood; Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood; Relapsed/Refractory B-cell Lymphoma, Childhood | name in intervention: CART-19 |
| NCT03853616 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Active not recruiting | Phase 1 | 2018-11-26 | 2026-11 | 48 | Acute Lymphoblastic Leukemia Recurrent; B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory; Chronic Lymphocytic Leukemia Recurrent; Chronic Lymphocytic Leukemia Refractory | name in intervention: CART-19 |
| NCT03685786 | CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT | Unknown | Phase 1 | 2018-06-01 | 2021-06-02 | 20 | Leukemia, Lymphocytic, Acute, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell | name in intervention: CART-19 |
| NCT03544021 | CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | Unknown | Phase 1/2 | 2018-03-01 | 2019-03-01 | 10 | Leukemia, Lymphocytic, Acute | name in intervention: CART-19 |
| NCT03455972 | Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT | Active not recruiting | Phase 1/2 | 2018-02-20 | 2027-12 | 43 | Safety and Efficacy | name in title: CART-19 |
| NCT03321123 | MB-CART19.1 in Patients With R/R ALL | Unknown | Phase 2 | 2017-12-01 | 2019-07-01 | 10 | Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory | name in intervention: CART-19 |
| NCT03896854 | CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Unknown | Phase 1/2 | 2017-10-18 | 2024-12-31 | 15 | Acute Myeloid Leukemia | intervention named: CART-19 |
| NCT03497819 | Autologous CARTmeso/19 Against Pancreatic Cancer | Unknown | Early phase 1 | 2017-10-01 | 2019-10-31 | 10 | Pancreatic Cancer | name in intervention: CART-19 |
| NCT03614858 | CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. | Unknown | Phase 1/2 | 2017-09-01 | 2024-12-31 | 20 | Leukemia, B-cell | name in intervention: CART-19 |
| NCT03027739 | CART-19 Cells For MRD Positive CD19+ ALL | Unknown | Phase 2/3 | 2016-11 | 2019-12 | 20 | Acute Lymphoblastic Leukemia | intervention named: CART-19 |
| NCT03101709 | The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma | Unknown | Phase 1 | 2016-08 | 2018-07 | 30 | B Cell Lymphoma | intervention named: CART-19 |
| NCT02924753 | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | Unknown | Phase 1 | 2016-07-18 | 2019-07 | 20 | B-cell Acute Lymphoblastic Leukemia | name in intervention: CART-19 |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | Unknown | Phase 1 | 2016-05 | 2017-12 | 20 | Acute Lymphoblastic Leukemia | intervention named: CART-19 |
| NCT03391726 | CART-19 Cells for R/R B-cell Lymphoma | Unknown | Phase 2/3 | 2016-01-01 | 2019-12 | 20 | Relapsed or Refractory B-cell Lymphoma | name in intervention: CART-19 |
| NCT03391739 | CART-19 Cells For R/R B-ALL | Unknown | Phase 2/3 | 2016-01 | 2019-12 | 20 | Relapsed/Refractory B-cell ALL | name in intervention: CART-19 |
| NCT02799550 | Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL | Unknown | Phase 1 | 2015-10 | 2019-05 | 10 | Leukemia | name in intervention: CART-19 |
| NCT02081937 | CART-19 Immunotherapy in Mantle Cell Lymphoma | Unknown | Phase 1/2 | 2014-03 | 2018-12 | 2 | Hematopoietic/Lymphoid Cancer; Mantle Cell Lymphoma; Non-hodgkin Lymphoma,B Cell | name in title: CART-19 |
| NCT01864889 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 | Unknown | 2013-04 | 2017-04 | 12 | Adult Acute Lymphoblastic Leukemia in Remission; B-cell Adult Acute Lymphoblastic Leukemia; B-cell Chronic Lymphocytic Leukemia; Hematopoietic/Lymphoid Cancer; Prolymphocytic Leukemia; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma | name in title: CART-19 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40610008 | Detection of HIV RNA after CAR T-Cell Therapy in a Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patient: Possibility of False Positivity and Clinical Implications. | Cancer research and treatment | 2026 | name in abstract: tisagenlecleucel |
| PMID 41252666 | Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | cited by trial NCT02445248 |
| PMID 41437832 | Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis. | Haematologica | 2026 | name in abstract: tisagenlecleucel |
| PMID 41508112 | Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure. | Journal of hematology & oncology | 2026 | name in abstract: tisagenlecleucel |
| PMID 41536778 | Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas. | Blood neoplasia | 2026 | cited by trial NCT03876028 |
| PMID 41747197 | Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. | Blood advances | 2026 | name in abstract: tisagenlecleucel |
| PMID 41765136 | Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41856668 | Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2026 | name in abstract: tisagenlecleucel |
| PMID 42136039 | Emapalumab for Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome Following CD19-Directed CAR-T in Two Patients With B-ALL: Clinical and Biomarker Correlates. | Pediatric blood & cancer | 2026 | name in abstract: tisagenlecleucel |
| PMID 42178058 | Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies. | Transplantation and cellular therapy | 2026 | name in abstract: tisa-cel |
| PMID 42285114 | Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study. | The Lancet. Haematology | 2026 | name in abstract: tisagenlecleucel |
| PMID 42285354 | Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42341302 | Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. | The New England journal of medicine | 2026 | cited by trial NCT02030834 |
| PMID 42469167 | HLH-like syndromes associate with increased risk of death and CD19- relapse after CAR T in pediatric B-ALL. | Blood advances | 2026 | name in abstract: tisagenlecleucel |
| PMID 42525896 | Long-Term Clinical Outcomes of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory ALL. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026 | cited by trial NCT02435849 |
| PMID 42629429 | Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. | Bone marrow transplantation | 2026 | name in abstract: tisagenlecleucel |
| PMID 42727020 | Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults. | Blood advances | 2026 | name in title: tisagenlecleucel |
| PMID 38781944 | Eosinophilic Pleocytosis in the Cerebrospinal Fluid following CAR-T Cell Therapy for Central Nervous System Lymphoma: A Case for Warning? | Acta haematologica | 2025 | name in abstract: tisagenlecleucel |
| PMID 39617098 | Real-world Outcomes of Commercial Tisagenlecleucel for Children, Adolescents, and Young Adults With Acute Lymphoblastic Leukemia in Japan. | Transplantation and cellular therapy | 2025 | name in title: tisagenlecleucel |
| PMID 39817702 | Role of procalcitonin, C-reactive protein and ferritin in cytokine release syndrome after CAR T-cell therapy in children and young adults. | Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals | 2025 | name in abstract: tisagenlecleucel |
| PMID 39894508 | Multiple Ulcers with Perforations of the Small Intestine in the Acute Phase of CD19 Chimeric Antigen Receptor T-cell Therapy Possibly Associated with Tocilizumab Administration. | Internal medicine (Tokyo, Japan) | 2025 | name in abstract: tisagenlecleucel |
| PMID 39938007 | Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. | Blood | 2025 | name in abstract: tisagenlecleucel |
| PMID 39998830 | Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma. | JAMA network open | 2025 | name in abstract: tisagenlecleucel |
| PMID 40085546 | Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP-ALL After Tisagenlecleucel: A Case Series. | Cancer reports (Hoboken, N.J.) | 2025 | name in title: tisagenlecleucel |
| PMID 40090005 | Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study. | Blood | 2025 | name in abstract: tisagenlecleucel |
| PMID 40203192 | Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study. | Blood advances | 2025 | name in abstract: tisagenlecleucel |
| PMID 40246539 | Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2025 | name in abstract: tisagenlecleucel |
| PMID 40377509 | Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial. | Cytotherapy | 2025 | name in title: tisagenlecleucel |
| PMID 40438977 | CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study. | Haematologica | 2025 | name in abstract: tisagenlecleucel |
| PMID 40589238 | Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience. | British journal of haematology | 2025 | name in abstract: tisa-cel |
| PMID 40690779 | Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel. | Blood advances | 2025 | name in title: tisagenlecleucel |
| PMID 40815804 | Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma. | Blood advances | 2025 | name in abstract: tisagenlecleucel |
| PMID 40903902 | Isolated oral CD30+/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in abstract: tisagenlecleucel |
| PMID 41348007 | Maintenance after CAR T? Are we there yet? Reducing the risk of relapse after loss of anti-CD19 CAR T-cell persistence in ALL. | Hematology. American Society of Hematology. Education Program | 2025 | name in abstract: tisagenlecleucel |
| PMID 41671463 | Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | cited by trial NCT03876769 |
| PMID 37883795 | CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study. | Blood | 2024 | cited by trial NCT04234061 |
| PMID 38114616 | Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy. | European journal of nuclear medicine and molecular imaging | 2024 | name in abstract: tisagenlecleucel |
| PMID 38194692 | Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update. | Blood | 2024 | cited by trial NCT03568461 |
| PMID 38316549 | Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation. | European journal of haematology | 2024 | name in abstract: tisagenlecleucel |
| PMID 38318174 | Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time. | Frontiers in immunology | 2024 | name in abstract: tisagenlecleucel |
| PMID 38359407 | Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma. | Blood advances | 2024 | name in abstract: tisagenlecleucel |
| PMID 38448002 | [Sequential therapy with inotuzumab ozogamicin followed by CAR T-cell therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia]. | [Rinsho ketsueki] The Japanese journal of clinical hematology | 2024 | name in abstract: tisagenlecleucel |
| PMID 38552193 | Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024 | name in abstract: tisagenlecleucel |
| PMID 38569863 | [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma]. | [Rinsho ketsueki] The Japanese journal of clinical hematology | 2024 | name in abstract: tisagenlecleucel |
| PMID 38594876 | Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK. | British journal of haematology | 2024 | name in abstract: tisagenlecleucel |
| PMID 38622139 | Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme. | Blood cancer journal | 2024 | name in title: tisagenlecleucel |
| PMID 38735758 | Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia. | British journal of haematology | 2024 | name in title: tisagenlecleucel |
| PMID 38895058 | Severe anaphylaxis after chimeric antigen receptor T-cell injection: a case report. | EJHaem | 2024 | name in abstract: tisagenlecleucel |
| PMID 38953781 | A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas. | Blood cancer discovery | 2024 | name in title: tisagenlecleucel |
| PMID 39069076 | Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO. | Transplantation and cellular therapy | 2024 | name in abstract: tisagenlecleucel |
| PMID 39098011 | [Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation]. | [Rinsho ketsueki] The Japanese journal of clinical hematology | 2024 | name in abstract: tisagenlecleucel |
| PMID 39108768 | Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments. | Cureus | 2024 | name in abstract: tisagenlecleucel |
| PMID 39252248 | Transformed follicular lymphoma with laryngeal edema requiring tracheal intubation after tisagenlecleucel treatment: A case report. | Medicine | 2024 | name in title: tisagenlecleucel |
| PMID 39304585 | CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast phase. | Annals of hematology | 2024 | name in abstract: Kymriah |
| PMID 39396632 | Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study. | Transplantation and cellular therapy | 2024 | name in abstract: tisagenlecleucel |
| PMID 39580601 | EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy. | Scientific reports | 2024 | name in abstract: tisagenlecleucel |
| PMID 39589371 | Aggressive Lymphoma after CD19 CAR T-Cell Therapy. | The New England journal of medicine | 2024 | name in abstract: tisagenlecleucel |
| PMID 39651063 | Prolonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis in a patient with acute lymphoblastic leukemia. | Blood cell therapy | 2024 | name in abstract: tisagenlecleucel |
| PMID 39935222 | [PET-CT positive lesions suggestive of pseudoprogression during long-term follow-up after complete remission with CAR-T cell therapy]. | [Rinsho ketsueki] The Japanese journal of clinical hematology | 2024 | name in abstract: tisagenlecleucel |
| PMID 36044388 | Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results. | Blood advances | 2023 | cited by trial NCT03630159 |
| PMID 36182104 | Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study. | Transplantation and cellular therapy | 2023 | name in title: tisagenlecleucel |
| PMID 36351239 | Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. | Blood | 2023 | name in abstract: tisagenlecleucel |
| PMID 36399695 | Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | cited by trial NCT02435849 |
| PMID 36404384 | Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. | International journal of hematology | 2023 | name in title: tisagenlecleucel |
| PMID 36508286 | Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. | Blood advances | 2023 | name in abstract: tisagenlecleucel |
| PMID 36690387 | Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report. | Journal for immunotherapy of cancer | 2023 | name in abstract: tisagenlecleucel |
| PMID 36937957 | Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation. | Frontiers in pediatrics | 2023 | name in title: tisagenlecleucel |
| PMID 36964939 | Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study. | European journal of haematology | 2023 | name in abstract: tisagenlecleucel |
| PMID 37027246 | Clofarabine for Lymphodepletion Before CAR-T-Cell Infusion: A Brief Case Report. | Journal of pediatric hematology/oncology | 2023 | name in abstract: tisagenlecleucel |
| PMID 37284193 | Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. | Frontiers in oncology | 2023 | name in abstract: tisagenlecleucel |
| PMID 37303362 | Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. | Cureus | 2023 | name in abstract: tisa-cel |
| PMID 37400640 | CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. | Nature medicine | 2023 | name in abstract: tisagenlecleucel |
| PMID 37659694 | Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study. | Transplantation and cellular therapy | 2023 | name in abstract: tisa-cel |
| PMID 37708442 | Chimeric antigen receptor T-cell immunotherapies adverse events reported to FAERS database: focus on cytopenias. | Leukemia & lymphoma | 2023 | name in abstract: tisagenlecleucel |
| PMID 37842456 | Anti-CD19 Chimeric Antigen Receptor T Cell Therapy With Tisagenlecleucel for Secondary Central Nervous System Lymphoma: A Case Series. | Cureus | 2023 | name in title: tisagenlecleucel |
| PMID 38022532 | Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models. | Frontiers in immunology | 2023 | cited by trial NCT04855253 |
| PMID 34233446 | Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. | Haematologica | 2022 | name in abstract: tisagenlecleucel |
| PMID 34727319 | Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients. | Frontiers of medicine | 2022 | name in abstract: tisagenlecleucel |
| PMID 34767461 | Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022 | name in abstract: tisagenlecleucel |
| PMID 34852305 | Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. | Transplantation and cellular therapy | 2022 | name in abstract: tisagenlecleucel |
| PMID 34904798 | Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. | The New England journal of medicine | 2022 | cited by trial NCT03570892 |
| PMID 34921238 | Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. | Nature medicine | 2022 | cited by trial NCT03568461 |
| PMID 35028140 | Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel. | Clinical case reports | 2022 | name in title: tisagenlecleucel |
| PMID 35030634 | Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. | Blood advances | 2022 | name in title: tisagenlecleucel |
| PMID 35167655 | Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. | Blood | 2022 | cited by trial NCT02445248 |
| PMID 35337365 | Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. | Experimental hematology & oncology | 2022 | cited by trial NCT02445248 |
| PMID 35341689 | Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2022 | name in title: tisagenlecleucel |
| PMID 35349631 | Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. | Blood advances | 2022 | cited by trial NCT02640209 |
| PMID 35422096 | Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. | Leukemia | 2022 | cited by trial NCT02228096 |
| PMID 35646299 | Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports). | Therapeutic advances in hematology | 2022 | name in abstract: tisagenlecleucel |
| PMID 35724631 | Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. | Acta haematologica | 2022 | name in title: tisagenlecleucel |
| PMID 35850429 | Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. | Transplantation and cellular therapy | 2022 | name in title: tisagenlecleucel |
| PMID 35944603 | Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma. | Transplantation and cellular therapy | 2022 | name in abstract: tisagenlecleucel |
| PMID 35973192 | Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. | Blood advances | 2022 | cited by trial NCT03568461 |
| PMID 36084658 | Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study. | The Lancet. Haematology | 2022 | name in title: tisagenlecleucel |
| PMID 36466893 | Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report. | Frontiers in immunology | 2022 | name in abstract: Kymriah |
| PMID 36714263 | Severe bloody diarrhea due to cytokine release syndrome after chimeric antigen receptor T cell therapy for refractory acute lymphoblastic leukemia. | Blood cell therapy | 2022 | name in abstract: tisagenlecleucel |
| PMID 32496443 | Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia. | Journal of pediatric hematology/oncology | 2021 | name in abstract: tisagenlecleucel |
| PMID 33009894 | Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia. | Pediatric blood & cancer | 2021 | name in abstract: tisagenlecleucel |
| PMID 33288485 | Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. | Clinical lymphoma, myeloma & leukemia | 2021 | cited by trial NCT03570892 |
| PMID 33417474 | Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021 | cited by trial NCT02906371 |
| PMID 33472856 | Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection. | Journal for immunotherapy of cancer | 2021 | name in title: tisagenlecleucel |
| PMID 33496754 | Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. | Blood advances | 2021 | cited by trial NCT02228096 |
| PMID 33608749 | Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. | European journal of clinical pharmacology | 2021 | name in abstract: tisagenlecleucel |
| PMID 34166502 | CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. | Blood | 2021 | name in abstract: tisagenlecleucel |
| PMID 34310745 | Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. | American journal of hematology | 2021 | cited by trial NCT02445248 |
| PMID 34322864 | Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation. | British journal of haematology | 2021 | name in title: tisagenlecleucel |
| PMID 34353848 | Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT02228096 |
| PMID 34432863 | Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. | Blood advances | 2021 | cited by trial NCT02228096 |
| PMID 34515338 | Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. | The Cochrane database of systematic reviews | 2021 | cited by trial NCT02030834 |
| PMID 34516954 | Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. | The Lancet. Oncology | 2021 | cited by trial NCT02445248 |
| PMID 34560014 | CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. | The Lancet. Haematology | 2021 | name in abstract: tisagenlecleucel |
| PMID 34597381 | Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia. | Blood advances | 2021 | name in title: tisagenlecleucel |
| PMID 34697176 | Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment. | In vivo (Athens, Greece) | 2021 | name in title: tisagenlecleucel |
| PMID 35111036 | Acute Lymphoblastic Leukemia Relapse Limited to the Anterior Chamber of the Eye and Treated with Novel CAR T-Cell Therapy. | Case reports in ophthalmology | 2021 | name in abstract: tisagenlecleucel |
| PMID 31709501 | Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia. | International journal of hematology | 2020 | name in title: tisagenlecleucel |
| PMID 31815579 | Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020 | cited by trial NCT01029366 |
| PMID 31973908 | Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2020 | name in abstract: tisagenlecleucel |
| PMID 32045475 | Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. | Blood advances | 2020 | cited by trial NCT02445248 |
| PMID 32074277 | Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. | Blood advances | 2020 | cited by trial NCT02445248 |
| PMID 32074609 | Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the Median. | Acta haematologica | 2020 | name in title: tisagenlecleucel |
| PMID 32271898 | Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. | Blood advances | 2020 | cited by trial NCT02445248 |
| PMID 32271899 | Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. | Blood advances | 2020 | cited by trial NCT02445248 |
| PMID 32298202 | Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020 | cited by trial NCT02640209 |
| PMID 32426735 | Extracorporeal Membrane Oxygenation as a Bridge to Chimeric Antigen Receptor T-cell Therapy for Severe Refractory Sepsis in the Setting of Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia: A Case Report. | Critical care explorations | 2020 | name in abstract: tisagenlecleucel |
| PMID 32448949 | Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. | International journal of clinical oncology | 2020 | name in title: tisagenlecleucel |
| PMID 32589970 | Hyper-CVAD: a regimen for all seasons. | The Lancet. Haematology | 2020 | cited by trial NCT03876769 |
| PMID 32744738 | Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. | American journal of hematology | 2020 | name in abstract: tisagenlecleucel |
| PMID 30309857 | FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | name in title: tisagenlecleucel |
| PMID 30489654 | Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis. | Journal of clinical apheresis | 2019 | name in abstract: tisagenlecleucel |
| PMID 30501490 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. | The New England journal of medicine | 2019 | cited by trial NCT02445248 |
| PMID 30670684 | The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. | Blood cancer journal | 2019 | name in abstract: tisagenlecleucel |
| PMID 31332046 | Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. | Blood advances | 2019 | cited by trial NCT02445248 |
| PMID 31606419 | Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. | The Lancet. Oncology | 2019 | cited by trial NCT02435849 |
| PMID 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | The New England journal of medicine | 2018 | cited by trial NCT02435849 |
| PMID 29669777 | False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. | Blood | 2018 | name in title: tisagenlecleucel |
| PMID 29669947 | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. | JCI insight | 2018 | cited by trial NCT02135406 |
| PMID 30178481 | Neurotoxicity after CTL019 in a pediatric and young adult cohort. | Annals of neurology | 2018 | cited by trial NCT01626495 |
| PMID 30190371 | Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2018 | name in title: tisagenlecleucel |
| PMID 30275568 | Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. | Nature medicine | 2018 | name in abstract: CTL019 |
| PMID 30572564 | Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report. | International journal of molecular sciences | 2018 | name in abstract: tisagenlecleucel |
| PMID 29226764 | Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. | The New England journal of medicine | 2017 | cited by trial NCT02030834 |
| PMID 26813675 | Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. | Blood | 2016 | cited by trial NCT01747486 |
| PMID 27166358 | Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. | Blood | 2016 | name in abstract: CTL019 |
| PMID 26352815 | Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. | The New England journal of medicine | 2015 | cited by trial NCT02135406 |
| PMID 25317870 | Chimeric antigen receptor T cells for sustained remissions in leukemia. | The New England journal of medicine | 2014 | cited by trial NCT01029366 |
| PMID 23527958 | Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. | The New England journal of medicine | 2013 | name in abstract: CTL019 |
| PMID 27632680 | cited by trial NCT01626495 | |||
| PMID 29925499 | cited by trial NCT02624258 | |||
| PMID 31076448 | cited by trial NCT01029366 | |||
| PMID 42575986 | cited by trial NCT02030834 |
Other papers
Preclinical studies, reviews and other papers that name it, newest 100 shown.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39410883 | Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System. | Expert opinion on drug safety | 2026 | name in abstract: tisagenlecleucel |
| PMID 40665713 | Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. | Cancer research and treatment | 2026 | name in title: tisagenlecleucel |
| PMID 40968610 | Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study. | Cancer research and treatment | 2026 | name in abstract: tisagenlecleucel |
| PMID 41026960 | Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel. | Blood advances | 2026 | name in title: tisagenlecleucel |
| PMID 41038347 | Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41138816 | Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41344219 | Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study. | Cytotherapy | 2026 | name in title: tisagenlecleucel |
| PMID 41345759 | Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review. | PharmacoEconomics | 2026 | name in abstract: tisagenlecleucel |
| PMID 41391508 | Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41396346 | Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. | PharmacoEconomics - open | 2026 | name in abstract: tisagenlecleucel |
| PMID 41401431 | A Tetrameric Biotin-Avidin Scaffold Using Anti-CD19 (FMC63) Traptavidin Fusion Enables High-Avidity CAR-T Cells for Leukemia Therapy. | Bioconjugate chemistry | 2026 | name in abstract: Kymriah |
| PMID 41448297 | Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis. | Critical reviews in oncology/hematology | 2026 | name in abstract: tisagenlecleucel |
| PMID 41492445 | Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis. | Therapeutic advances in hematology | 2026 | name in abstract: tisagenlecleucel |
| PMID 41496894 | CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. | Molecular therapy. Nucleic acids | 2026 | name in abstract: Kymriah |
| PMID 41507382 | Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma? | Bone marrow transplantation | 2026 | name in title: tisagenlecleucel |
| PMID 41529329 | Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma. | Cytotherapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41544566 | Real-world outcomes of tisagenlecleucel treatment in patients with relapsed or refractory large B-cell lymphomas: a nationwide registry. | Cytotherapy | 2026 | name in title: tisagenlecleucel |
| PMID 41544567 | Establishing practical predictors of collection efficiency for optimized chimeric antigen receptor T-cell apheresis. | Cytotherapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41546434 | Brain Microstructural Damage as Potential Biomarker of Immune Cell-Associated Neurotoxicity Syndrome. | Journal of neuroimaging : official journal of the American Society of Neuroimaging | 2026 | name in abstract: tisagenlecleucel |
| PMID 41560109 | Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System. | Medicine | 2026 | name in abstract: tisagenlecleucel |
| PMID 41578095 | The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer. | Nature reviews. Clinical oncology | 2026 | name in abstract: tisagenlecleucel |
| PMID 41579860 | CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL. | Cell reports. Medicine | 2026 | name in title: tisagenlecleucel |
| PMID 41639434 | Tisagenlecleucel yields superior patient-reported health-related quality of life compared to autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas. | Annals of hematology | 2026 | name in title: tisagenlecleucel |
| PMID 41689916 | Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma. | Cytotherapy | 2026 | name in title: tisagenlecleucel |
| PMID 41701431 | Value of information analyses for advanced cell therapies: a systematic review. | Health economics review | 2026 | name in abstract: tisagenlecleucel |
| PMID 41729209 | The Use of Targeted Therapy in Pediatric Acute Lymphoblastic Leukemia: Exploring Novel Approaches and Emerging Therapies. | Current treatment options in oncology | 2026 | name in abstract: tisagenlecleucel |
| PMID 41735483 | Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia. | Leukemia | 2026 | name in title: tisagenlecleucel |
| PMID 41748023 | Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41762956 | Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy. | Cytotherapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41772123 | Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma? | Bone marrow transplantation | 2026 | name in title: tisagenlecleucel |
| PMID 41828393 | Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy. | International journal of molecular sciences | 2026 | name in abstract: tisagenlecleucel |
| PMID 41857785 | A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends. | Biomarker research | 2026 | name in abstract: tisagenlecleucel |
| PMID 41858754 | The evolving landscape of CAR T cell therapy in children and young adults with B cell acute lymphoblastic leukemia. | Molecular therapy. Oncology | 2026 | name in abstract: tisagenlecleucel |
| PMID 41867486 | Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas. | Blood neoplasia | 2026 | name in abstract: tisagenlecleucel |
| PMID 41935222 | Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy. | Bone marrow transplantation | 2026 | name in abstract: tisagenlecleucel |
| PMID 41935576 | Neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 41951449 | Infections Post-CAR-T Therapy: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database. | Clinical therapeutics | 2026 | name in abstract: tisa-cel |
| PMID 41953008 | Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy. | Frontiers in immunology | 2026 | name in abstract: tisagenlecleucel |
| PMID 41959729 | Preinfusion risk factors for the development of severe neurotoxicity following CART therapy in pediatric patients. | HemaSphere | 2026 | name in abstract: tisagenlecleucel |
| PMID 41964291 | Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response. | Transfusion | 2026 | name in abstract: tisa-cel |
| PMID 42001436 | Metabolic changes in reticuloendothelial system following Tisagenlecleucel chimeric antigen receptor T cell (CAR-T) therapy using 18F-FDG PET/CT. | Hellenic journal of nuclear medicine | 2026 | name in title: tisagenlecleucel |
| PMID 42018609 | Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis. | Blood advances | 2026 | name in abstract: tisagenlecleucel |
| PMID 42086512 | Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis. | American journal of hematology | 2026 | name in abstract: tisagenlecleucel |
| PMID 42109668 | Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study. | Frontiers in oncology | 2026 | name in title: tisagenlecleucel |
| PMID 42114808 | Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42138782 | Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. | Advances in therapy | 2026 | name in title: tisagenlecleucel |
| PMID 42173255 | Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42245166 | Understanding access to novel high-cost cancer therapies across Canada: a national survey of pediatric oncology providers. | Frontiers in pediatrics | 2026 | name in abstract: tisagenlecleucel |
| PMID 42251173 | Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT. | Bone marrow transplantation | 2026 | name in abstract: tisagenlecleucel |
| PMID 42257985 | Drug-associated cytokine release syndrome: a FAERS pharmacovigilance study with complementary transcriptomic analysis. | Naunyn-Schmiedeberg's archives of pharmacology | 2026 | name in abstract: tisagenlecleucel |
| PMID 42265809 | Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL. | Stem cell research & therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42269079 | Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma. | Blood advances | 2026 | name in abstract: tisagenlecleucel |
| PMID 42279369 | Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience. | Cancers | 2026 | name in abstract: tisagenlecleucel |
| PMID 42297689 | Gastrointestinal toxicity in the treatment of hematological tumors. Influence on nutritional status. | Endocrinologia, diabetes y nutricion | 2026 | name in abstract: tisa-cel |
| PMID 42329247 | Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma. | Oncology (Williston Park, N.Y.) | 2026 | name in abstract: tisagenlecleucel |
| PMID 42341926 | Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42359427 | Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves. | Cureus | 2026 | name in abstract: tisagenlecleucel |
| PMID 42381271 | Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database. | Japanese journal of clinical oncology | 2026 | name in abstract: tisagenlecleucel |
| PMID 42428526 | Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis. | PeerJ | 2026 | name in title: tisagenlecleucel |
| PMID 42449670 | Real-World Dermatologic Adverse Events of CAR T-Cell Therapy: A Decade-Wide Disproportionality Analysis of the FDA Adverse Event Reporting System. | Cancers | 2026 | name in abstract: tisagenlecleucel |
| PMID 42527721 | Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing. | Current oncology reports | 2026 | name in abstract: tisagenlecleucel |
| PMID 42556536 | Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42568509 | CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies. | Frontiers in immunology | 2026 | name in abstract: tisagenlecleucel |
| PMID 42583745 | Real-World Data from a Single-Center, Large Academic Centralized Manufacturing of CD19 CAR T Cells in an Industry Partnership. | Human gene therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42610412 | Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma. | Haematologica | 2026 | name in title: tisagenlecleucel |
| PMID 42636161 | T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia. | Blood | 2026 | name in abstract: CTL019 |
| PMID 42642819 | Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis From Korea. | Journal of Korean medical science | 2026 | name in title: tisagenlecleucel |
| PMID 42645791 | Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL. | Hematology reports | 2026 | name in abstract: tisagenlecleucel |
| PMID 42650392 | Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study. | Children (Basel, Switzerland) | 2026 | name in title: tisagenlecleucel |
| PMID 42660975 | Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy. | Leukemia | 2026 | name in title: tisa-cel |
| PMID 42663433 | InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL. | European journal of haematology | 2026 | name in abstract: tisa-cel |
| PMID 42675139 | Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome. | Leukemia | 2026 | name in title: tisagenlecleucel |
| PMID 42732974 | Could Mixed CAR T-Cell Products and Overlapping Patients Overestimate the Risk of HLH With Tisagenlecleucel? | American journal of hematology | 2026 | name in title: tisagenlecleucel |
| PMID 42777835 | Host immune biomarkers associated with infection risk after CAR T-cell therapy. | The Journal of infection | 2026 | name in abstract: tisagenlecleucel |
| PMID 42790202 | Transient suppression of fibrinolytic potential during cytokine release syndrome after chimeric antigen receptor T-cell therapy in B-cell malignancies. | Thrombosis research | 2026 | name in abstract: tisagenlecleucel |
| PMID 42844744 | Immune effector cell-associated neurotoxicity syndrome in hematological malignancy patients treated with CAR-T cell: A systematic review. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research | 2026 | name in abstract: tisagenlecleucel |
| PMID 42844780 | CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital. | Acta clinica Belgica | 2026 | name in abstract: tisagenlecleucel |
| PMID 42896626 | Favorable Survival for Older Adults Treated With Axi-cel and Tisa-cel CD19 CAR-T Therapy for Relapsed/Refractory DLBCL: A U.S. Multicenter Comparative Analysis. | Transplantation and cellular therapy | 2026 | name in title: tisa-cel |
| PMID 42906792 | Predictors and Outcomes of Immune Effector Cell- Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Aggressive B Cell Non-Hodgkin Lymphoma. | Transplantation and cellular therapy | 2026 | name in abstract: tisagenlecleucel |
| PMID 42908664 | Comparative real-world pharmacovigilance analysis of adverse event signals associated with six approved CAR-T products using the FAERS database. | Frontiers in pharmacology | 2026 | name in abstract: Kymriah |
| PMID 42926043 | Allogeneic stem cells transplantation in children, adolescents and young adults previously treated by tisagenlecleucel for B-cell precursor acute lymphoblastic leukemia: a French retrospective SFGM-TC study. | Transplantation and cellular therapy | 2026 | name in title: tisagenlecleucel |
| PMID 42938906 | Longitudinal Flow Cytometric Profiling of CAR-T and Endogenous T Cells Following CD19 CAR-T Therapy. | Cancers | 2026 | name in abstract: tisagenlecleucel |
| PMID 42951655 | [CAR-T cell therapy for acute lymphoblastic leukemia: current landscape and novel developments]. | [Rinsho ketsueki] The Japanese journal of clinical hematology | 2026 | name in abstract: tisagenlecleucel |
| PMID 42968286 | Long-term outcomes and immune reconstitution after tisagenlecleucel in relapsed or refractory large B-cell lymphoma: a single-institution retrospective study in Japan with over 3 years follow-up. | Journal of clinical and experimental hematopathology : JCEH | 2026 | name in title: tisagenlecleucel |
| PMID 43010892 | Impaired ex vivo T-cell expansion before leukapheresis is associated with out-of-specification tisagenlecleucel manufacturing in pediatric CD19+ALL. | Frontiers in immunology | 2026 | name in title: tisagenlecleucel |
| PMID 43019612 | Model-predicted fludarabine exposure and outcomes after tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. | Cytotherapy | 2026 | name in title: tisagenlecleucel |
| PMID 43026080 | Secondary cancer after CAR-T cell therapy: A French pharmacovigilance analysis. | Therapie | 2026 | name in abstract: tisagenlecleucel |
| PMID 43026256 | Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition. | Bone marrow transplantation | 2026 | name in abstract: tisagenlecleucel |
| PMID 39316713 | The present and future of CAR T-cell therapy for adult B-cell ALL. | Blood | 2025 | name in abstract: tisagenlecleucel |
| PMID 39415689 | Eleven cases of laryngeal edema after tisagenlecleucel infusion: a 3-year single center retrospective study of CD19-directed chimeric antigen receptor T-cell therapy for relapsed and refractory B-cell lymphomas. | Haematologica | 2025 | name in title: tisagenlecleucel |
| PMID 39418599 | Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network. | Blood advances | 2025 | name in abstract: tisagenlecleucel |
| PMID 39562721 | Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study. | Leukemia | 2025 | name in abstract: tisagenlecleucel |
| PMID 39666878 | Dynamics of Immune Reconstitution and Impact on Outcomes across CAR-T Cell Products in Large B-cell Lymphoma. | Blood cancer discovery | 2025 | name in abstract: tisagenlecleucel |
| PMID 39680322 | Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) DLBCL with CAR T Cell Therapy: A Vodcast and Case Example. | Oncology and therapy | 2025 | name in abstract: tisagenlecleucel |
| PMID 39680351 | Outcomes of allogeneic SCT versus tisagenlecleucel in patients with R/R LBCL and poor prognostic factors. | International journal of hematology | 2025 | name in title: tisagenlecleucel |
| PMID 39704157 | Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome. | Haematologica | 2025 | name in abstract: tisa-cel |
| PMID 39779930 | T cell malignancies after CAR T cell therapy in the DESCAR-T registry. | Nature medicine | 2025 | name in abstract: tisagenlecleucel |
| PMID 39846935 | Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome. | Cytotherapy | 2025 | name in abstract: tisagenlecleucel |
| PMID 39883946 | Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel. | Blood advances | 2025 | name in abstract: tisagenlecleucel |
Unconfirmed matches (1)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41183747 | Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma. | Transplantation and cellular therapy | 2026 | name in title: CART-19 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P30CA016520 | Pediatric Oncology Program | UNIVERSITY OF PENNSYLVANIA | GRUPP, STEPHAN A. | 2021–2026 | name in abstract: tisagenlecleucel |
| P30CA016672 | Stem Cell Biology & Cellular Therapy Program | UNIVERSITY OF TX MD ANDERSON CAN CTR | SHPALL, ELIZABETH J | 2019–2026 | name in abstract: tisagenlecleucel |
| R01CA309280 | Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumors | CHILDREN'S HOSP OF PHILADELPHIA | MA, LEYUAN | 2026–2026 | name in abstract: Kymriah |
| R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | HACKENSACK UNIVERSITY MEDICAL CENTER | ZAKRZEWSKI, JOHANNES | 2022–2026 | name in abstract: Kymriah |
| UH3CA283652 | Next generation T cell therapies for mutant KRAS solid tumors | UNIVERSITY OF PENNSYLVANIA | CARRENO, BEATRIZ M. | 2025–2026 | name in abstract: Kymriah |
| UG3CA283652 | Next generation T cell therapies for mutant KRAS solid tumors | UNIVERSITY OF PENNSYLVANIA | CARRENO, BEATRIZ M. | 2023–2024 | name in abstract: Kymriah |
| ZIABC011780 | Clinical development of mechanism-based lymphoma therapies | DIVISION OF BASIC SCIENCES - NCI | STAUDT, LOUIS | 2024–2024 | name in abstract: tisagenlecleucel |
| U01CA232361 | Defining and overcoming intrinsic T cell dysfunction to enable pediatric immunotherapy | CHILDREN'S HOSP OF PHILADELPHIA | GRUPP, STEPHAN A. | 2019–2019 | name in abstract: tisagenlecleucel |
| U54CA232568 | Understanding and Overcoming Resistance to Immunotherapies in Childhood Cancers | CHILDREN'S HOSP OF PHILADELPHIA | MACKALL, CRYSTAL | 2018–2018 | name in abstract: tisagenlecleucel |
Unconfirmed matches (2)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| P01CA214278 | Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19 | UNIVERSITY OF PENNSYLVANIA | JUNE, CARL H. | 2017–2026 | name in title: CART-19 |
| R01CA288473 | Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation | UNIVERSITY OF PENNSYLVANIA | FACCIABENE, ANDREA | 2025–2026 | name in title: CART-19 |
Notes
Lentiviral anti-CD19 (FMC63) 4-1BB CAR. CART-19 also used generically for other CD19 CARs (ambiguous).
How to cite
tisagenlecleucel (AXP000013.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000013.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.